Antiviral method

Abstract

This invention provides a method of inactivating non-enveloped virus particles. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and enhancers selected from cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof.

1 . A virucidally-enhanced alcoholic composition comprising:
 (a) at least 50 wt. % of a C 1-6  alcohol, based upon the total weight of the alcoholic composition;   (b) a first enhancer selected from the group consisting of polyquaternium polymers, cationic polyalkylene imines, cationic ethoxy polyalkylene imines, cationic poly[N-[3-(dialkylammonio)alkyl]N′[3-(alkyleneoxyalkylene dialkylammonio)alkyl]urea dichloride], vinyl caprolactam/VP/dialkylaminoalkyl alkylate copolymers, and mixtures thereof; and   (c) a second enhancer selected from the group consisting of proton donors, chaotropic agents, and mixtures thereof, wherein said enhancers enhance the efficacy of the alcohol against non-enveloped viruses.   
     
     
         2 . The composition of  claim 1 , wherein said virucidal composition exhibits an efficacy against non-enveloped viruses that is at least about 1 log kill higher than the efficacy of the same composition but not comprising said first and second enhancers. 
     
     
         3 . The composition of  claim 1 , wherein said composition comprises from about 0.02 to about 20 percent by weight of a cationic oligomer or polymer, based upon the total weight of the alcoholic composition. 
     
     
         4 . The composition of  claim 1 , wherein said first enhancer is selected from the group consisting of polyquaternium polymers. 
     
     
         5 . The composition of  claim 1 , wherein said cationic oligomer or polymer is a polyquaternium selected from the group consisting of polyquaternium-2, polyquaternium-4, polyquaternium-5, polyquaternium-6, polyquaternium-7, polyquaternium-10, polyquaternium-11, polyquaternium-16, polyquaternium-22, polyquaternium-24, polyquaternium-28, polyquaternium-32, polyquaternium-37, polyquaternium-39, polyquaternium-42, polyquaternium-43, polyquaternium-44, polyquaternium-46, polyquaternium-47, polyquaternium-51, polyquaternium-53, polyquaternium-55, polyquaternium-57, polyquatemium-58, polyquatemium-59, polyquaternium-60, polyquaternium-63, polyquaternium-64, polyquaternium-65, polyquaternium-68, and mixtures thereof. 
     
     
         6 . The composition of  claim 1 , wherein said composition comprises from about 0.015 to about 1 percent by weight of a proton donor, based upon the total weight of the alcoholic composition. 
     
     
         7 . The composition of  claim 6 , wherein said proton donor comprises hydrochloric acid, nitric acid, phosphoric acid, phosphonic acid, boric acid, sulfuric acid, adipic acid, benzene 1,3,5 tricarboxylic acid, chlorosuccinic acid, choline chloride, cis-aconitic acid, citramalic acid, citric acid, cyclobutane 1,1,3,3 tetracarboxylic acid, cyclohexane 1,2,4,5 tetracarboxylic acid, cyclopentane 1,2,3,4 tetracarboxylic acid, diglycolic acid, fumaric acid, glutamic acid, glutaric acid, glyoxylic acid, isocitric acid, ketomalonic acid, lactic acid, maleic acid, malic acid, malonic acid, nitrilotriacetic acid, oxalacetic acid, oxalic acid, phytic acid, p-toluenesulfonic acid, salicylic acid, succinic acid, tartaric acid, tartronic acid, tetrahydrofuran 2,3,4,5 tetracarboxylic acid, tricarballylic acid, versene acids, 3-hydroxyglutaric acid, 2-hydroxypropane 1,3 dicarboxylic acid, glyceric acid, furan 2,5 dicarboxylic acid, 3,4-dihydroxyfuran-2,5 dicarboxylic acid, 3,4-dihydroxytetrahydrofuran-2,5-dicarboxylic acid, 2-oxo-glutaric acid, dl-glyceric acid, 2,5 furandicarboxylic acid, or a mixture thereof. 
     
     
         8 . The composition of  claim 1 , wherein said composition comprises from about 0.25 to about 20 percent by weight chaotropic agent, based upon the total weight of the alcoholic composition. 
     
     
         9 . The composition of  claim 8 , wherein said chaotropic agent comprises urea, thiourea, guanidine HCl, guanidine thiocyanate, aminoguanidine HCl, aminoguanidine bicarbonate, guanidine carbonate, guanidine phosphate, or a mixture thereof. 
     
     
         10 . The composition of  claim 8 , wherein said chaotropic agent is selected from the group consisting of urea, thiourea, guanidine HCl, guanidine thiocyanate, aminoguanidine HCl, and mixtures thereof. 
     
     
         11 . The composition of  claim 1 , wherein said second enhancer is selected from the group consisting of citric acid, lactic acid, malic acid, tartaric acid, salicylic acid, oxalic acid, and mixtures thereof. 
     
     
         12 . A virucidally-enhanced alcoholic composition comprising:
 (a) at least 50 wt. % of a C 1-6  alcohol, based upon the total weight of the alcoholic composition;   (b) a first enhancer selected from the group consisting of cationic oligomers and polymers; and   (c) a second enhancer selected from the group consisting of proton donors, chaotropic agents, and mixtures thereof, wherein said enhancers enhance the efficacy of the alcohol against non-enveloped viruses, and wherein said composition includes no more than about 0.1 wt. % of an auxiliary antimicrobial agent.   
     
     
         13 . A method of inactivating non-enveloped virus particles, the method comprising:
 contacting non-enveloped virus particles with a virucidally-enhanced alcoholic composition comprising (a) at least 50 wt. % of a C 1-6  alcohol, based upon the total weight of the alcoholic composition; (b) a first enhancer selected from the group consisting of polyquatemium polymers, cationic polyalkylene imines, cationic ethoxy polyalkylene imines, cationic poly[N[3-(dialkylammonio)alkyl]N′[3-(alkyleneoxyalkylene dialkylammonio)alkyl]urea dichloride], vinyl caprolactam/VP/dialkylaminoalkyl alkylate copolymers, and mixtures thereof; and (c) a second enhancer selected from the group consisting of proton donors, chaotropic agents, and mixtures thereof.   
     
     
         14 . A method of inactivating non-enveloped virus particles, the method comprising: contacting non-enveloped virus particles with a virucidally-enhanced alcoholic composition comprising (a) at least 50 wt. % of a C 1-6  alcohol, based upon the total weight of the alcoholic composition; (b) an enhancer selected from the group consisting of polyquatemium polymers, cationic polyalkylene imines, cationic ethoxy polyalkylene imines, cationic poly[N-[3-(dialkylammonio)alkyl]N′[3-(alkyleneoxyalkylene dialkylammonio)alkyl]urea dichloride], vinyl caprolactam/VP/dialkylaminoalkyl alkylate copolymers, and mixtures thereof; and optionally including from about 0.1 to about 1 wt. % of at least one auxiliary antimicrobial agent. 
     
     
         15 . The method of  claim 14 , wherein said auxiliary antimicrobial agent is selected from the group consisting of triclosan; chloroxylenol; hexetidine; chlorhexidine salts; salts of N,N″-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,14-tetraazatetradecanediimidi amide; 2-bromo-2-nitropropane-1; 3-diol, benzalkonium chloride; cetylpyridinium chloride; alkylbenzyldimethylammonium chlorides; iodine; phenol derivatives, povidone-iodine; polyvinylpyrrolidinone-iodine; parabens; hydantoins; 2,4-imidazolidinedione; dimethylol-5,5-dimethylhydantoin; phenoxyethanol; quaternium-15; diazolidinyl urea; benzethonium chloride; methylbenzethonium chloride; silver compounds, copper compounds, magnesium compounds, zinc compounds; hydrogen peroxide, chorine dioxide, and mixtures thereof. 
     
     
         16 . The method of  claim 14 , wherein said cationic oligomer or polymer includes polyquaternium-2, polyquatemium-4, polyquatemium-5, polyquatemium-6, polyquaternium-7, polyquatemium-10, polyquatemium-11, polyquatemium-16, polyquaternium-22, polyquaternium-24, polyquatemium-28, polyquaternium-32, polyquaternium-37, polyquaternium-39, polyquaternium-42, polyquaternium-43, polyquatemium-44, polyquaternium-46, polyquaternium-47, polyquaternium-51, polyquaternium-53, polyquaternium-55, polyquatemium-57, polyquaternium-58, polyquaternium-59, polyquatemium-60, polyquaternium-63, polyquatemium-64, polyquaternium-65, polyquaternium-68, or mixtures thereof. 
     
     
         17 . The method of  claim 14 , wherein said method exhibits an increased log reduction against said non-enveloped virus particles, when compared to the log reduction of a composition comprising the same amount of said C 1-6  alcohol, but not comprising said enhancer. 
     
     
         18 . The method of  claim 14 , wherein said method exhibits at least a 1 log reduction against said non-enveloped virus particles in 60 seconds or less. 
     
     
         19 . The method of  claim 14 , wherein said method exhibits at least a 3 log reduction against said non-enveloped virus particles in 60 seconds or less. 
     
     
         20 . The method of  claim 14 , wherein said non-enveloped virus particles are selected from members of the families Picornaviridae, Reoviridae, Caliciviridae, Adenoviridae and Parvoviridae. 
     
     
         21 . The method of  claim 14 , wherein said non-enveloped virus particles are selected from adenovirus, feline calicivirus, norovirus, papillomavirus, poliovirus, rhinovirus, hepatitis A virus, parvovirus, and rotavirus. 
     
     
         22 . The method of  claim 14 , wherein said cationic oligomer or polymer is selected from the group consisting of polyquaternium-2, polyquaternium-4, polyquaternium-6, polyquaternium-7, polyquatemium-11, polyquaternium-16, polyquatemium-22, polyquaternium-28, polyquaternium-32, polyquaternium-37, polyquaternium-39, polyquaternium-42, polyquatemium-47, polyquaternium-51, polyquaternium-53, polyquaternium-55, polyquaternium-58, polyquatemium-68, and mixtures thereof. 
     
     
         23 . The method of  claim 14 , wherein said auxiliary antimicrobial agent is selected form copper compounds.